123 related articles for article (PubMed ID: 7848333)
1. Effect of the platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride on endotoxin-induced hypotension and hematological parameters in rats.
Natsume Y; Imanishi N; Koike H; Morooka S
Arzneimittelforschung; 1994 Nov; 44(11):1208-13. PubMed ID: 7848333
[TBL] [Abstract][Full Text] [Related]
2. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
3. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
Toth PD; Mikulaschek AW
Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig.
Bernat A; Herbert JM; Salel V; Lespy L; Maffrand JP
J Lipid Mediat; 1992 Feb; 5(1):41-8. PubMed ID: 1391738
[TBL] [Abstract][Full Text] [Related]
5. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
Komuro Y; Imanishi N; Uchida M; Morooka S
Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Effects on microvascular permeability, hypotension and nephrosis.
Sakuma Y; Shirato M; Nagaoka J; Obaishi H; Tsunoda H; Katayama S; Ono H; Katayama K
Arzneimittelforschung; 1991 Dec; 41(12):1255-9. PubMed ID: 1815526
[TBL] [Abstract][Full Text] [Related]
7. Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).
Imanishi N; Komuro Y; Morooka S
Lipids; 1991 Dec; 26(12):1391-5. PubMed ID: 1819739
[TBL] [Abstract][Full Text] [Related]
8. Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats.
Qi M; Jones SB
Circ Shock; 1990 Oct; 32(2):153-63. PubMed ID: 2253318
[TBL] [Abstract][Full Text] [Related]
9. A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats.
Murakami K; Okajima K; Uchiba M; Johno M; Okabe H; Takatsuki K
Thromb Haemost; 1996 Jun; 75(6):965-70. PubMed ID: 8822594
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
Fernández-Gallardo S; Ortega MP; Priego JG; de Casa-Juana MF; Sunkel C; Sánchez Crespo M
J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of endotoxin-induced increase in glucose metabolism by platelet-activating factor antagonist.
Lang CH; Dobrescu C; Hargrove DM; Bagby GJ; Spitzer JJ
Circ Shock; 1987; 23(3):179-88. PubMed ID: 3427772
[TBL] [Abstract][Full Text] [Related]
12. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.
Kawamura M; Kitayoshi T; Terashita Z; Fujiwara S; Takatani M; Nishikawa K
J Lipid Mediat Cell Signal; 1994 May; 9(3):255-65. PubMed ID: 7921785
[TBL] [Abstract][Full Text] [Related]
13. Platelet-activating factor antagonists in experimental shock.
Muacevic G; Heuer HO
Arzneimittelforschung; 1992 Aug; 42(8):1001-4. PubMed ID: 1418068
[TBL] [Abstract][Full Text] [Related]
14. Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury. The role of PAF and tumor necrosis factor.
Sun XM; Hsueh W; Torre-Amione G
Am J Pathol; 1990 Apr; 136(4):949-56. PubMed ID: 2327475
[TBL] [Abstract][Full Text] [Related]
15. Comparative hemodynamics and cardiovascular effects of endotoxin and platelet-activating factor in rat.
Salari H; Demos M; Wong A
Circ Shock; 1990 Nov; 32(3):189-207. PubMed ID: 2261677
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
Wu MS; Biftu T; Doebber TW
J Pharmacol Exp Ther; 1986 Dec; 239(3):841-5. PubMed ID: 3795043
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086.
Wilson DV; Eberhart SW; Robinson NE; Rice R; Gray PR
Am J Vet Res; 1993 Feb; 54(2):274-9. PubMed ID: 8430938
[TBL] [Abstract][Full Text] [Related]
18. Effects of platelet-activating factor antagonist SRI 63-441 on endotoxin-induced changes in rat mesenteric microcirculation.
Li SH; Fei X; Gong XQ; Wu ZL
Yao Xue Xue Bao; 1991; 26(1):6-9. PubMed ID: 1887797
[TBL] [Abstract][Full Text] [Related]
19. Platelet activating factor impairs pressor responses to noradrenaline in the anaesthetized rat but does not mediate endotoxin-induced hyporeactivity.
Bouvier C; Guc MO; Furman BL; Parratt JR
Circ Shock; 1994 Jan; 42(1):14-9. PubMed ID: 8149505
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats.
Akagi M; Nishioka E; Kanoh R; Tachibana M; Fukuishi N
Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]